Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax(TM) Treatment

Trial Profile

Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax(TM) Treatment

Discontinued
Phase of Trial: Phase III

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs Nelipepimut-S (Primary) ; Sargramostim
  • Indications Breast cancer; Early breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms PRESENT
  • Sponsors Galena Biopharma
  • Most Recent Events

    • 09 Nov 2016 According to a Galena Biopharma media release, management will present the top-line data from the trial and its assessment of the results in conference call.
    • 09 Aug 2016 Company has initiated an investigation into the causes of the the Independent Data Monitoring Committee (IDMC) recommendation to stop the trial, according to a Galena Biopharma media release.
    • 09 Aug 2016 Company has shared the PRESENT trial information with the investigators of two other trials (see profile 210321 and 243798) and these trial will continue as as planned, according to a Galena Biopharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top